Will watch but it is amazingly weak. Seems like a approval is priced in and now everybody is concerned about mid term issues with bring the drug to market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.